Retatrutide Meds

CITATIONS

Retatrutide References

Every quantitative claim on this site maps to a numbered citation below. DOIs and PubMed URLs included.

Full citation index

All citations are numbered [1]–[16] as used in the text. Each entry includes DOI and PubMed or PMC link where available.

  1. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. ↗
  2. Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. Lancet. 2023;402(10401):529-544. ↗
  3. Li W, Zhou Q, Cong Z, et al. Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. Cell Discovery. 2024;10:77. ↗
  4. Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400:1869-1881. ↗
  5. Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30:2037-2048. ↗
  6. Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K. Retatrutide — A Game Changer in Obesity Pharmacotherapy. Biomolecules. 2025;15:796. ↗
  7. Drucker DJ, et al. Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity. Diabetes Care. 2024;47(11):1873-1888. ↗
  8. Melson E, et al. What is the pipeline for future medications for obesity? Int J Obes. 2025;49(3):433-451. ↗
  9. Phillips R, et al. Nutrient-stimulated Hormone-based Therapies: A New Frontier in the Prevention and Management of MASH-associated Hepatocellular Carcinoma. J Clin Transl Hepatol. 2025;13(12):1060-1066. ↗
  10. Cho YK, et al. Engineered nutrient-stimulated hormonal multi-agonists for precision targeting of obesity and metabolic disorders. Clin Mol Hepatol. 2026;32(2):464-486. ↗
  11. Muzurović E, et al. Emerging incretin- and multi-agonist-based treatments — the continued refinement and continuous expansion of a potent therapeutic armamentarium for cardio-kidney-liver-metabolic diseases and beyond. Metabolism. 2026;177:156494. ↗
  12. Bajaj HS, et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet. 2026. doi:10.1016/S0140-6736(26)00967-0. ↗
  13. Lempesis IG, et al. Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies. Metabolism Open. 2026. doi:10.1016/j.metop.2026.100463. ↗
  14. Panou T, et al. Retatrutide in type 2 diabetes mellitus and obesity: an overview. Expert Rev Clin Pharmacol. 2026. doi:10.1080/17512433.2026.2642415. ↗
  15. Alavi SE, et al. Multi-target incretin-based therapeutics: The rise of dual and triple agonists for metabolic disorders. Eur J Med Chem. 2026. doi:10.1016/j.ejmech.2026.118587. ↗
  16. Cho YK, et al. (see [10]) — body composition data referenced from Lancet Diabetes Endocrinol 2025 substudy on lean mass (RETATRUTIDE-41f18601 stable_id; confirmed from Phase 2 body composition substudy). See also: Alavi SE [15] for lean mass context. ↗